Healthcare sector team

Analysts

Dr Nathaniel Calloway

Dr Nathaniel Calloway
Associate Healthcare Analyst

Pooya Hemami

Pooya Hemami
Analyst

Dr Charlotte Hetzel

Dr Charlotte Hetzel
Analyst

Dr Dennis Hulme

Dr Dennis Hulme
Analyst

Maxim Jacobs

Maxim Jacobs
Director of Healthcare Research, North America

Dr Susie Jana

Dr Susie Jana
Analyst

Dr Jonas Peciulis

Dr Jonas Peciulis
Analyst

Dr John Savin

Dr John Savin
Analyst

Juan Pedro Serrate

Juan Pedro Serrate
Associate Analyst

Briana Warschun

Briana Warschun
Associate Healthcare Analyst

Dr Daniel Wilkinson

Dr Daniel Wilkinson
Analyst

By region

Recent initiations

Cellular Biomedicine Group Sierra Oncology
Laboratorios Farmacéuticos ROVI Therapix Biosciences
NeuroVive Pharmaceutical MagForce

Recent QuickViews

Race Oncology

Rediscovering a lost chemotherapeutic

Pharmaceutical & healthcare | published 26/09/2017
aap Implantate

Exploring strategic alternatives to add value

Pharmaceutical & healthcare | published 17/08/2017
CSL

Continued growth from plasma and vaccines

Pharmaceutical & healthcare | published 03/08/2017
Rovi

Enoxaparin biosimilars - natural evolution

Pharmaceutical & healthcare | published 15/06/2017

Would you like to be notified when new research is published? Access our research RSS feed

Latest research

Hutchison China MediTech

WCLC highlights savolitinib combination potential

ADR Update | Pharmaceutical & healthcare | 19/10/2017

Data presented at the World Conference on Lung Cancer (WCLC) on combination approaches to treat resistant EGFR-driven non-small cell lung cancer (NSCLC)…

Pluristem Therapeutics

Grants and collaborations to support development

Update | Pharmaceutical & healthcare | 18/10/2017

Pluristem now has three ongoing clinical programs: critical limb ischemia (CLI, Phase III), intermittent claudication (IC, Phase II) and the acute radiation…

Hutchison China MediTech

WCLC highlights savolitinib combination potential

Update | Pharmaceutical & healthcare | 18/10/2017

Data presented at the World Conference on Lung Cancer (WCLC) on combination approaches to treat resistant EGFR-driven non-small cell lung cancer (NSCLC)…

MorphoSys

Termination of coverage

Update | Pharmaceutical & healthcare | 16/10/2017

Edison Investment Research is terminating coverage on MorphoSys (MOR). Please note you should no longer rely on any previous research or estimates for…

Newron Pharmaceuticals

Xadago launched; eyes now on pipeline assets

Outlook | Pharmaceutical & healthcare | 13/10/2017

Following an encouraging year to date we have upgraded our forecasts for Xadago (Parkinson’s disease [PD] therapy), and key CNS pipeline assets sarizotan…

Sector commentary

See more reports See more reports See more reports

Sector reports

See more sector reports See more sector reports See more sector reports

Sectors covered

Pharmaceutical & healthcare Show companies